ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
nChroma Bio
nChroma Bio is developing engineered epigenetic silencers for treating diseases affecting the liver, blood, cardiovascular, and central nervous systems. The company focuses on next-generation genomic medicines with a patient-centric approach, supported by leading scientists and investors.
nChroma Bio is a genetic medicines company based in Boston that takes a disease-first approach to therapeutic design. The company combines best-in-class genetic cargoes with targeted in vivo delivery technologies to develop potent and durable treatments addressing areas of high unmet need. nChroma Bio operates in the biotechnology industry with a focus on overcoming the limitations of current gene therapy approaches.
Fierce BiotechGenetic medicine outfit nChroma sheds staff in research reorg
Nov 12, 2025
CRISPR MedicinenChroma Bio clears first clinical hurdle for CRISPR-based epigenetic HBV therapy
Dec 17, 2025
Business WirenChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B
Dec 16, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for nChroma Bio.
78% above the average for this role
BioSpacenChroma Bio Presents Preclinical Data Demonstrating Epigenetic Silencing Approach as a Potential Functional Cure for Chronic Hepatitis B at AASLD 2025
Nov 10, 2025
Director, Regulatory Affairs CMC
Corcept Therapeutics
Regulatory Affairs Associate Director, CMC
Novartis
Senior Director, Regulatory Affairs CMC Europe
Cytokinetics
Director, CMC Regulatory Affairs
Jobgether
Director, Regulatory Affairs CMC
Generate:Biomedicines
Director, Regulatory Affairs, CMC
BrainChild Bio, Inc.
